数据表2：中国晚期野生型鳞状非小细胞肺癌的11种治疗路径效果与成本效益分析

数据集获取（Figshare）

• 源站标题：Data_Sheet_2_Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.PDF
• DOI：10.3389/fpubh.2023.1051484.s002
• 发布日期：2023-02-24
• 文件数：1 个
• 文件总体积：143.19 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_2_Effectiveness_and_cost-effectiveness_analysis_of_11_treatment_paths_seven_first-line_and_three_second-line_treatments_for_Chinese_patients_with_advanced_wild-type_squamous_non-small_cell_lung_cancer_A_sequential_model_PDF/22153223

命令行下载

curl -L -o "Data_Sheet_2_Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patien.PDF" "https://ndownloader.figshare.com/files/39383936"

文件清单

• Data_Sheet_2_Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patien.PDF（143.19 KB）

文件总体积 143.19 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundA total of 11 treatment sequences for advanced wild-type squamous non-small cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines, consisting of seven first-line and three second-line treatments. Five of these treatments were newly approved in China between 2021 and 2022. We evaluated the effectiveness and cost-effectiveness of these strategies from the Chinese healthcare system perspective.
MethodsNetwork meta-analysis with non-proportional hazards was used to calculate the relative efficacy between interventions. A sequential model was developed to estimate costs and quality-adjusted life years (QALY) for treatment sequences with first-line platinum- and paclitaxel-based chemotherapy (SC) with or without nedaplatin, tislelizumab, camrelizumab, sintilimab, sugemalimab or pembrolizumab, followed by second-line docetaxel, tislelizumab or nivolumab. SC and docetaxel were used as comparators for first-line and second-line treatments, respectively. QALY and incremental cost-effectiveness ratio (ICER) were used to evaluate effectiveness and cost-effectiveness, respectively. Cost-effective threshold was set as USD 19,091. Subgroup analysis was conducted to determine the best first-line and second-line therapy.
ResultsPembrolizumab + SC, followed by docetaxel (PED) was the most effective treatment sequence. QALYs for patients received SC, nedaplatin + SC, tislelizumab + SC, sintilimab + SC, camrelizumab + SC, sugemalimab + SC, pembrolizumab + SC followed by docetaxel were 0.866, 0.906, 1.179, 1.266, 1.179, 1.266, 1.603, 1.721, 1.807; QALYs for SC, nedaplatin + SC followed by tislelizumab were 1.283, 1.301; QALYs for SC, nedaplatin + SC followed by nivolumab were 1.353, 1.389. Camrelizumab + SC, followed by docetaxel (CAD) was the most cost-effective. Compared to SC with or without nedaplatin, tislelizumab, or sintilimab followed by docetaxel, ICERs of CAD were USD 12,276, 13,210, 6,974, 9,421/QALY, respectively. Compared with nedaplatin or SC followed by tislelizumab, the ICERs of CAD were USD 4,183, 2,804/QALY; CAD was dominant compared with nedaplatin or SC followed by nivolumab; The ICER of sugemalimab + SC followed by docetax

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fpubh.2023.1051484.s002（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_2_Effectiveness_and_cost-effectiveness_analysis_of_11_treatment_paths_seven_first-line_and_three_second-line_treatments_for_Chinese_patients_with_advanced_wild-type_squamous_non-small_cell_lung_cancer_A_sequential_model_PDF/22153223）。